The spike protein of SARS-CoV — a target for vaccine and therapeutic development

Severe acute respiratory syndrome (SARS) is a newly emerging infectious disease caused by a novel coronavirus, SARS-coronavirus (SARS-CoV). The SARS-CoV spike (S) protein is composed of two subunits; the S1 subunit contains a receptor-binding domain that engages with the host cell receptor angiotens...

Descripción completa

Detalles Bibliográficos
Autores principales: Du, Lanying, He, Yuxian, Zhou, Yusen, Liu, Shuwen, Zheng, Bo-Jian, Jiang, Shibo
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2009
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2750777/
https://www.ncbi.nlm.nih.gov/pubmed/19198616
http://dx.doi.org/10.1038/nrmicro2090
_version_ 1782172241351409664
author Du, Lanying
He, Yuxian
Zhou, Yusen
Liu, Shuwen
Zheng, Bo-Jian
Jiang, Shibo
author_facet Du, Lanying
He, Yuxian
Zhou, Yusen
Liu, Shuwen
Zheng, Bo-Jian
Jiang, Shibo
author_sort Du, Lanying
collection PubMed
description Severe acute respiratory syndrome (SARS) is a newly emerging infectious disease caused by a novel coronavirus, SARS-coronavirus (SARS-CoV). The SARS-CoV spike (S) protein is composed of two subunits; the S1 subunit contains a receptor-binding domain that engages with the host cell receptor angiotensin-converting enzyme 2 and the S2 subunit mediates fusion between the viral and host cell membranes. The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity, during infection with SARS-CoV. In this Review, we highlight recent advances in the development of vaccines and therapeutics based on the S protein.
format Text
id pubmed-2750777
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-27507772009-09-24 The spike protein of SARS-CoV — a target for vaccine and therapeutic development Du, Lanying He, Yuxian Zhou, Yusen Liu, Shuwen Zheng, Bo-Jian Jiang, Shibo Nat Rev Microbiol Article Severe acute respiratory syndrome (SARS) is a newly emerging infectious disease caused by a novel coronavirus, SARS-coronavirus (SARS-CoV). The SARS-CoV spike (S) protein is composed of two subunits; the S1 subunit contains a receptor-binding domain that engages with the host cell receptor angiotensin-converting enzyme 2 and the S2 subunit mediates fusion between the viral and host cell membranes. The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity, during infection with SARS-CoV. In this Review, we highlight recent advances in the development of vaccines and therapeutics based on the S protein. Nature Publishing Group UK 2009-02-09 2009 /pmc/articles/PMC2750777/ /pubmed/19198616 http://dx.doi.org/10.1038/nrmicro2090 Text en © Nature Publishing Group 2009 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Article
Du, Lanying
He, Yuxian
Zhou, Yusen
Liu, Shuwen
Zheng, Bo-Jian
Jiang, Shibo
The spike protein of SARS-CoV — a target for vaccine and therapeutic development
title The spike protein of SARS-CoV — a target for vaccine and therapeutic development
title_full The spike protein of SARS-CoV — a target for vaccine and therapeutic development
title_fullStr The spike protein of SARS-CoV — a target for vaccine and therapeutic development
title_full_unstemmed The spike protein of SARS-CoV — a target for vaccine and therapeutic development
title_short The spike protein of SARS-CoV — a target for vaccine and therapeutic development
title_sort spike protein of sars-cov — a target for vaccine and therapeutic development
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2750777/
https://www.ncbi.nlm.nih.gov/pubmed/19198616
http://dx.doi.org/10.1038/nrmicro2090
work_keys_str_mv AT dulanying thespikeproteinofsarscovatargetforvaccineandtherapeuticdevelopment
AT heyuxian thespikeproteinofsarscovatargetforvaccineandtherapeuticdevelopment
AT zhouyusen thespikeproteinofsarscovatargetforvaccineandtherapeuticdevelopment
AT liushuwen thespikeproteinofsarscovatargetforvaccineandtherapeuticdevelopment
AT zhengbojian thespikeproteinofsarscovatargetforvaccineandtherapeuticdevelopment
AT jiangshibo thespikeproteinofsarscovatargetforvaccineandtherapeuticdevelopment
AT dulanying spikeproteinofsarscovatargetforvaccineandtherapeuticdevelopment
AT heyuxian spikeproteinofsarscovatargetforvaccineandtherapeuticdevelopment
AT zhouyusen spikeproteinofsarscovatargetforvaccineandtherapeuticdevelopment
AT liushuwen spikeproteinofsarscovatargetforvaccineandtherapeuticdevelopment
AT zhengbojian spikeproteinofsarscovatargetforvaccineandtherapeuticdevelopment
AT jiangshibo spikeproteinofsarscovatargetforvaccineandtherapeuticdevelopment

Ejemplares similares